Presented By Marco Colleoni at 2017 ASCO Annual Meeting SOLE (Study of Letrozole Extension)<br /><br />A phase 3 randomized clinical trial of <br />continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting S LE Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Slide 3 Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Extended Adjuvant Endocrine Therapy <br />for HR+ Early Breast Cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Alternating “on-off” Letrozole Treatment as a Therapeutic Option to Prolong Sensitivity to Endocrine Treatment Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Effect of intermittent letrozole treatment in <br />MCF-7Ca xenografts Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Questions in Extended Adjuvant Endocrine Therapy <br />in HR+ Early Breast Cancer Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting SOLE: Study of Letrozole Extension<br />After 4 to 6 years of Prior Adjuvant Endocrine Therapy<br />Postmenopausal, HR-positive, Node-positive Presented By Marco Colleoni at 2017 ASCO Annual Meeting

SOLE Quality of Life Substudy Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Eligibility and Procedures Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Endpoints Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Statistical Considerations Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Characteristics Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Results Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Primary Endpoint: Disease-Free Survival Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Sites of First DFS Event Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Breast Cancer-Free Interval Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Distant Recurrence-Free Interval Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Overall Survival Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting Treatment Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Selected Adverse Events: Worst Grade Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Quality of Life:<br />Change from Baseline to 12 and 24 Months Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting SOLE: Conclusions Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting SOLE: Conclusions Presented By Marco Colleoni at 2017 ASCO Annual Meeting

Presented By Marco Colleoni at 2017 ASCO Annual Meeting IBCSG Thanks Presented By Marco Colleoni at 2017 ASCO Annual Meeting